ALPROLIX 3000 IU powder and solvent for solution for injection

Drug information

POM

Read time: 1 mins

Last updated: 16 Jun 2021

Summary of product characteristics

1. Name of the medicinal product

2. Qualitative and quantitative composition

4.2. Posology and method of administration

4.4. Special warnings and precautions for use

4.5. Interaction with other medicinal products and other forms of interaction

4.6. Fertility, pregnancy and lactation

4.7. Effects on ability to drive and use machines

5.1. Pharmacodynamic properties

5.2. Pharmacokinetic properties

6.4. Special precautions for storage

6.5. Nature and contents of container

6.6. Special precautions for disposal and other handling

7. Marketing authorisation holder

8. Marketing authorisation number(s)

9. Date of first authorisation/renewal of the authorisation

10. Date of revision of the text

4.1 Therapeutic indications

4.2 Posology and method of administration

4.3 Contraindications

4.4 Special warnings and precautions for use

4.5 Interaction with other medicinal products and other forms of interaction

4.6 Fertility, pregnancy and lactation

4.7 Effects on ability to drive and use machines

4.8 Undesirable effects

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).